Bioequivalence Study of Metamizole Sodium 500 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Metamizole Sodium 500 mg film-coated tablets in healthy participants under fasting conditions. Bioequivalence studies are crucial in determining whether a generic product releases its active ingredient into the bloodstream at the same rate and extent as the original branded product. This is clinically relevant as it ensures therapeutic equivalence, allowing for safe substitution of the generic product for the branded one without compromising efficacy or safety.

The clinical trial involves a study population that includes both **female** and **male** participants, with an age range category code of 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants were selected without any specific medical condition being a requirement, as indicated by the absence of a defined medical condition for inclusion. The sponsor has not provided information regarding lifestyle considerations such as diet, physical activity, or habits. Additionally, no principal inclusion criteria have been specified for this trial. The sponsor has not given further information regarding the selection process or additional demographic details.

The clinical trial is designed to evaluate the **bioequivalence** of Metamizole Sodium 500 mg film-coated tablets in healthy participants under fasting conditions. This study is a Phase 2 trial, which will be conducted as a randomized, double-blind, controlled trial to ensure the reliability and validity of the results. The estimated recruitment start date is November 11, 2024, with the trial expected to conclude by December 18, 2024. The trial does not involve any specific medical condition, as it is focused on healthy participants.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve obtaining informed consent, conducting baseline assessments, and ensuring participants meet the inclusion criteria. Following successful screening, participants will be randomized to receive either the test or reference product under fasting conditions. Subsequent follow-up visits will be scheduled to monitor the participants' health, collect pharmacokinetic data, and ensure adherence to the study protocol. The end-of-study visit will involve final assessments to evaluate the primary and secondary endpoints of the trial.

The expected length of participant involvement in the study is approximately one month, including the screening, treatment, and follow-up phases. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial is structured to maintain the highest ethical standards and ensure participant safety throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on November 11, 2024, with an estimated completion date of December 18, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to standard clinical trial protocols to ensure the accuracy and reliability of the efficacy assessments. The study will be conducted in accordance with regulatory requirements and ethical guidelines to ensure the integrity of the data collected.